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Abstract
Background: Due to maldigestion of dietary lipids, fat soluble vitamins are prone to malabsorption in cystic fibrosis (CF)
patients with pancreatic insufficiency (PICF). Routine supplementation of vitamin K in PICF is presently subject of discussion.1
Methods: Serum vitamin K, prothrombin time, PIVKA-II (‘liver marker’, by two different ELISAs), hydroxyapatite binding
capacity (HBC, ‘bone marker’) and ApoE genotypes were measured in 32 PICF patients (age: 7 months to 25 years) with
(PICFK) or without (PICFN) oral vitamin K supplementation, all receiving lipase supplementation, and in 18 healthy controls1
(C). Results: PIVKA-II was positive only in 4y7 PICFN. HBC medians of all groups were 57–60%. HBC values of PIVKA-II
positive patients were below HBC median of their group. There was no correlation between HBC and PIVKA-II. There was no
correlation between prothrombin time and other measurements. HBC medians with regard to ApoE were ApoE2y3 (62.9%))
ApoE3y3 (57.6%))ApoE3y4qApoE4y4s(56.65%). Conclusions: Vitamin K deficiency of liver or bone may occur indepen-
dently. Prothrombin time is an insensitive marker. Individuals with ApoE4 allels might be more susceptible to osteopenia. As
high expenditures are necessary to detect patients at risk, routine vitamin K supplementation for all PICF patients appears
appropriate.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Due to maldigestion of dietary lipids, fat soluble
vitamins are prone to malabsorption in cystic fibrosis
(CF) patients with pancreatic insufficiency. For this
reason, vitamins A, D, E and K are often supplemented
in these patients. Sokol et al. found in patients with CF
and pancreatic insufficiency deficiencies only of vitamin
A, D and E but not of vitamin K w1x. More recent
reports have detected subclinical vitamin K deficiency
in some individuals with CF, and the question of routine
supplementation of vitamin K (phylloquinone) in1
patients receiving adequate lipase supplementation has
become subject of discussion w2–4x.
*Corresponding author. Tel.: q49-211-8118590; fax: q49-211-
8116441.
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Vitamin K is an essential cofactor in the post-trans-
lational carboxylation of several proteins. In the liver, it
is responsible for carboxylation of coagulation factors
II, VII, IX and X. However, coagulopathy is an insen-
sitive marker of vitamin K deficiency, because it occurs
only if the amount of undercarboxylated coagulation
factors exceeds 50% w5x. Subclinical vitamin K defi-
ciency of liver metabolism can be detected by measure-
ment of undercarboxylated prothrombin, so-called
prothrombin induced by vitamin K absence (PIVKA-
II), using ELISA methods with specific monoclonal
antibodies w6x. Detection of PIVKA-II can so far be
regarded as the ‘golden standard’ of subclinical liver
vitamin K deficiency assessment because of its high
sensitivity and specificity. In bone metabolism, the
hydroxyapatite binding capacity of osteocalcin (HBC)
is dependent on its degree of vitamin K-mediated car-
boxylation. A low HBC caused by vitamin K insuffi-
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ciency has been found to be a marker predictive of
osteopenia and hip fractures in postmenopausal women
w7x.
In CF patients without liver disease, coagulopathy
caused by vitamin K deficiency is unusual if there is
adequate supplementation with pancreatic enzymes. The
liver has a highly effective mechanism for uptake of
vitamin K from the serum and can maintain sufficient
tissue concentrations even at low serum concentrations.
In contrast, bone metabolism is dependent on higher
vitamin K serum concentrations and hence has a higher
susceptibility to vitamin K deficiency w8,9x. Vitamin K
deficiency of the bone can exist in the absence of
vitamin K deficiency of the liver. In CF patients,
concerns refer much more to osteopenia caused by
chronic vitamin K deficiency than to coagulopathy. In
addition to malabsorption, frequent use of antibiotics
can contribute further to a Vitamin K deficient state in
CF patients.
A genetic influence on vitamin K status has been
reported by Saupe et al. w10x. Different apolipoprotein
E-genotypes (ApoE) were significantly associated with
different vitamin K serum concentrations in their study
on hemodialysis patients. Magnitude of vitamin K con-
centrations were related to ApoE allels in the order
E2)E3)E4. ApoE4 allels coincide with a higher clear-
ance-rate of chylomicrones, which are the main carriers
of serum vitamin K, than E3 and E2 allels. This is
associated with a concomitantly higher clearance-rate of
vitamin K, and a higher susceptibility for vitamin K
deficiency in patients with E4 allels has been suggested
w10x. While contribution of ApoE variants to the bone
mineral density and bone turnover possibly remains
obscured in young and healthy subjects, it becomes
manifest in elderly or diseased patients at higher risk of
accelerated bone loss w11x, thus possibly including
patients with CF.
In our study, we assessed vitamin K status by different
laboratory methods in 32 CF patients with or without
oral supplementation of vitamin K and in a control1
group of 18 healthy controls in order to find out about
different forms of vitamin K deficiency and to comple-
ment the recent discussion about the need of routine
supplementation of vitamin K in CF. We also examined
the influence of the different ApoE genotypes that are
supposed to represent a predictor of a particular suscep-
tibility to vitamin K deficiency.
2. Methods
2.1. Subjects
In this study, 32 patients with CF (age range: 7
months to 25 years) were involved. All of them had
confirmed CF by positive sweat tests andyor genetic
analysis. All patients had pancreatic insufficiency and
received supplementation of pancreatic enzymes, the
dose depending on clinical symptoms and fecal fat
measurements. Body weight was within the range from
75 to 137% of the height-for-weight standard. On
abdominal (duplex-)sonographic controls, two patients
showed significant liver impairment (nodules and portal
hypertension). Fifteen patients received oral ursodesox-
ycholic acid because of elevated gamma-glutamyltrans-
peptidase (GGT) in the past. At the time of blood
sampling, most of the CF patients (23 of 32) received
antibiotic treatment, either intravenously for 2 weeks or
orally as regular prophylaxis. Seven of the CF patients
received vitamin K supplementation (Konakion, Hoff-1
man–La Roche) at dosages between 6 and 20 mg per
week.
The 18 control cases (age range: 3 months to 24
years) of our study were individuals who came to our
outpatient clinics to have ruled out a disorder. All of
them were finally healthy.
All subjects in this study were fasting )8 h before
blood draw.
2.2. Laboratory tests
2.2.1. Vitamin K serum concentrations
Briefly, vitamin K serum concentrations were deter-
mined in 1-ml EDTA plasma samples by electrochemical
reduction and fluorometric detection as described by
Thijssen and Drittij-Reijnders w12x. The sample was
extracted twice with hexane, which was bound to a
silica sep-pack column. Vitamin K was then purified by
high performance liquid chromatography (HPLC). A
following isocratic chromatography was used for quan-
titative analysis of vitamin K (detailed methods w13x).
2.2.2. Serum lipid status
As suggested by Sadowski et al. w14x, we also
assessed vitamin K status in relation to plasma triglyc-
erides to correct for differences in transport. Samples of
2-ml EDTA-blood were collected to determine total
triglyceride concentrations. Concentrations were meas-
ured enzymatically.
2.2.3. Coagulation tests
Plasma (0.5 ml) anticoagulated with 0.05 ml 3.8%
sodium citrate was used to determine coagulation. By
routine coagulation assays we determined standard pro-
thrombin time (Quick test). Coagulation impairment
was defined as prothrombin time -80%.
2.2.4. PIVKA-II
After venipuncture, 0.5 ml of citrated blood was
centrifuged (2000=g, 15 min) and plasma was stored
at y70 8C. PIVKA-II concentrations were determined
by two different enzyme-linked immunoassays (ELI-
SA): We performed one assay distributed by Diagnos-
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Table 1
Comparison of CF patients without vitamin K supplementation, CF patients with vitamin K supplementation and control group
CF wyo CF with Control
vitamin K suppl. vitamin K suppl.
n 25 7 18
Age range 0; 7–25; 6 3; 10–19; 8 0; 3–24; 0
(years; months)
Vitamin K 363 789 574
(pgyml) (median)
Vitamin Kytriglycerides 367 998 524
(=10 ) (median)y6
PIVKA-II positive 4 – –
(n)
HBC 57 60 57
(%) (median)
Coagulopathy 6 3 –
(prothrombin time -80%)
Liver-cirrhosisa 1 1 –
Diagnosis of portal hypertension by duplex-sonography.a
tica STAGO (Asnieres-Sur-Seine, France) using a
P1-2B9 PIVKA-II antibody, and another assay devel-
oped by Motohara et al. using the ED023-050 antibody
w6x. In both methods, the monoclonal antibody is binding
to descarboxylated prothrombin without cross-reactivity
to native prothrombin. In a second step, the activity of
the linked peroxidase is measured by spectrometry.
PIVKA-II concentrations are expressed in ngyml (Diag-
nostica kit) and in arbitrary units (AU) per ml,
respectively w6x. We defined a blood sample as unam-
biguously PIVKA-II positive, when there was PIVKA-
II detected in both tests (any evidence of PIVKA-II in
the Motohara assay and G2 ngyml in the Diagnostica
assay).
2.2.5. HBC
To measure HBC, serum was prepared by incubating
venous blood for 20 min at room temperature followed
by centrifugation for 15 min at 2000=g. All serum
samples were frozen at y70 8C within 2 h after
venipuncture, and stored at this temperature until testing.
Total immunoreactive osteocalcin (irOC) concentrations
were measured by means of the radioimmunoassay kit
from Incstar (Stillwater, MN). Undercarboxylated osteo-
calcin was assessed after adsorption of 0.5-ml serum
with 50 mg of hydroxyapatite (BDH, Poole, UK), and
HBC values are expressed as the percentage of osteo-
calcin bound to hydroxyapatite. The normal range in
adults is approximately 70–80% w15x.
2.2.6. Apolipoprotein E genotypes
ApoE was determined by restriction fragment electro-
phoresis of genomic DNA amplified with the polymer-
ase chain reaction (PCR) w10x.
2.3. Statistics
Statistical analysis of the data was accomplished with
the aid of a computer package system SPSS 10.0 (simple
regression and Kruskal–Wallis test).
3. Results
Medians of vitamin K concentrations ranked in the
order: CF without supplementations364 pgyml-con-
trol casess574 pgyml-CF with supplementations789
pgyml (Table 1). Medians of the ratio vitamin Kyserum
triglycerides were as follows: CF without supplementa-
tions397=10 , control casess524=10 , CF withy6 y6
supplementations998=10 (Table 1).y6
PIVKA-II was detected in five patients by using the
Motohara method, and in 13 patients by using the
commercially available kit. There were only four
patients in whom PIVKA-II was detected by both ELISA
methods; all of them were in the group of CF patients
without supplementation. Furthermore, there were nine
patients with threshold results (2–19 ngyml) for PIV-
KA-II in the Diagnostica assay, but negative results in
the Motohara assay. Another sample was threshold
positive in the Motohara assay (-0.2 AUyml), but not
in the Diagnostica assay. For statistical evaluation, only
the four patients who showed positive results in both
assays were taken into account. Three of the four
patients in whom PIVKA-II was detected by both tests
also had coagulopathy with prothrombin time ranging
from 54 to 77%; one had normal coagulation activity.
The patient with lowest prothrombin time had the
highest PIVKA-II concentrations in both tests ()100
ngyml and )1 AUyml, respectively). The two patients
with liver impairment were PIVKA-II negative.
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Fig. 1. HBC levels (%) and PIVKA-II positive individuals in CF
patients without vitamin K supplementation (ns25), CF patients with
vitamin K supplementation (ns7) and controls (ns18). Medians,
quartiles and ranges of HBC levels (%) by boxplots.  symbols
represent PIVKA-II positive individuals at their level of HBC.
Fig. 2. HBC levels (%) of apolipoprotein (Apo) E2 (genotype
E2yE3), E3 (genotype E3yE3) and E4 (genotypes E3yE4 and E4yE4).
Medians, quartiles and ranges of HBC levels (%) by boxplots. Con-
sidered are only unsupplemented individuals (CF patients without
vitamin K supplementation and controls).
HBC medians of all three groups were in the range
of 57–60% (Table 1). HBC values of all PIVKA-II
positive patients were below HBC median of their group.
Fig. 1 shows that there are also patients with rather low
values of HBC, but PIVKA-II negative. There was no
correlation between HBC and PIVKA-II. Also, there
was no correlation between PIVKA-II and serum vitamin
K concentrations. The use of antibiotics did not correlate
with either PIVKA-II or HBC.
Coagulation impairment was detected in six CF
patients without supplementation (four of them PIVKA-
II positive in both tests), and in three CF patients with
supplementation, but in none of the control group (Table
1). There was no correlation between coagulation activ-
ity and vitamin K serum concentrations nor PIVKA-II
nor HBC.
Of all 47 individuals who had ApoE genotypes tested,
5y47 (10.6%) had genotype ApoE2y3, 25y47 (53.2%)
had ApoE3y3, 14y47 (29.8%) had ApoE3y4 and 3y47
(6.4%) had ApoE4y4.
When we looked at ApoE genotypes in unsupple-
mented individuals (CF and controls), they were not
associated with distinct serum concentrations of vitamin
K or vitamin Kytriglycerides. The medians of HBC
values in these individuals decreased with regard to
ApoE in the order ApoE2y3s62.9%)ApoE3y3s
57.6%)ApoE3y4qApoE4y4s56.65% (n.s.) (Fig. 2).
4. Discussion
Even at the status of balanced supplementation with
pancreatic enzymes, CF patients seem to have lower
absorption of lipids than healthy individuals w16x. Con-
comitantly to a diminished absorption of lipids, an
insufficient absorption of lipid-soluble vitamins such as
vitamin K is possible.
In our study, CF patients without vitamin K supple-
mentation had apparently, though not significantly, low-
est medians of vitamin K serum concentrations whether
assessed as absolute values or in relation to serum
triglycerides. Supplementation resulted in serum vitamin
K concentrations numerically even higher than those of
controls. This was already apparent in absolute vitamin
K concentrations, and became statistically significant
after correction for serum triglycerides, due to lower
triglycerides in CF patients.
There were four unambiguously PIVKA-II positive
patients only in the unsupplemented group. Hence, clear
evidence of subclinical vitamin K deficiency of the liver
was only detectable in unsupplemented CF patients.
Here, our data are not concurrent with data by Rashid
et al. w17x or Wilson et al. w2x, who measured PIVKA-
II in 78 and 81%, respectively, of unsupplemented
pancreatic-insufficient patients by means of the Diag-
nostica assay kit. As the Motohara assay reflects a
higher specificity, we considered those samples negative,
in which PIVKA-II was detected at threshold concentra-
tions of 2–19 ngyml by the Diagnostica assay while
not detected by the Motohara method. Our data on
PIVKA-II therefore reflect a very high specificity; this
is important because PIVKA-II is generally to be con-
sidered the ‘golden standard’ when assessing liver vita-
min K status. If we had applied the same criteria for
PIVKA-II detection as was done in the above-mentioned
studies (G3 ngyml in the Diagnostica assay), 12y25
unsupplemented patients would have been considered
positive.
In the absence of PIVKA-II, vitamin K deficiency is
unlikely to be the cause of coagulopathy w4x. The
coagulopathy observed in six PIVKA-II negative
patients (three of whom received supplementation with
vitamin K) is probably caused by other reasons, such as
95K. Mosler et al. / Journal of Cystic Fibrosis 2 (2003) 91–96
liver disease that had in most of these cases as yet
escaped diagnosis by laboratory and (duplex-) sono-
graphic examinations.
The medians of HBC in our three groups are low
compared to normal values in adults but they are in the
range of values measured by Grundberg et al. in 10
children w18x. The mechanism underlying the low HBC
in all children (healthy and diseased) may be the
increased vitamin K requirement of bone during rapid
growth. In childhood, osteocalcin production in bone is
much higher than in adults, which means that the
vitamin K requirement of bone is relatively high in
children, and that during growth bone is more prone to
develop vitamin K deficiency than during later phases
of life. The question remains, however, why HBC did
not improve substantially after vitamin K supplementa-
tion. Medians of HBC levels differed only slightly
between the three groups. PIVKA-II positive patients
showed HBC levels below the HBC median of their
group, but patients with lowest HBC levels were not
generally PIVKA-II positive. The latter can be explained
by a highly effective uptake mechanism of the liver for
vitamin K. The liver can apparently maintain a sufficient
supply of vitamin K even at low blood levels that may
cause vitamin K deficiency of bone metabolism w9x.
Still, in our study, patients with vitamin K deficiency of
the liver—as diagnosed by PIVKA-II—would not nec-
essarily have been diagnosed vitamin K deficient by
only assessing the bone marker HBC. Apparently, in CF,
vitamin K deficiency of either tissue can appear inde-
pendent from another. This corroborates the suggestion
that vitamin K deficiency is to be judged regarding
individual organs: Liver vitamin K deficiency as deter-
mined by PIVKA-II, vs. bone vitamin K deficiency as
determined by bone markers, HBC e.g. w9x.
An influence of ApoE genotypes on vitamin K status
has previously been reported by Saupe et al. w10x. They
obtained a significant correlation between ApoE allels
and serum vitamin K concentrations: ApoE2 allels were
associated with higher concentrations of serum vitamin
K than ApoE3 allels; ApoE3 allels again were associated
with higher concentrations of serum vitamin K than
ApoE4 allels. In their study, no corresponding associa-
tion of ApoE allels and HBC was found in hemodialysis
patients. However, a later study of similar patients by
the same study group reveiled a significantly higher
prevalence of bone fractures in patients carrying the
ApoE4 allel than in those carrying the ApoE2 allel w19x.
In our study, we found a ranking of the medians of
HBC levels in unsupplemented individuals in the order
ApoE2)ApoE3)ApoE4. This is in correspondence
with the theoretical background that ApoE4 genotypes
are associated with a higher clearance of triglycerides
and of vitamin K, thus predisposing to vitamin K
deficiency w14x. An influence of ApoE variants on bone
mineral density has been shown in several subgroups of
elderly or diseased subjects, but not in younger and
healthy persons w11x. As far as we know, there has never
before been a study regarding a marker of bone metab-
olism with respect to ApoE variants in CF patients. To
investigate the issue in depth, studies with higher num-
bers of CF patients would have to be performed in order
to examine whether CF patients with the rare ApoE4
allel have a higher risk of osteopenia.
From our data, vitamin K deficiency occurs only
rarely in patients with CF, and vitamin K deficiency of
the liver or of the bone may appear independent from
each other. Individuals with ApoE4 allels tend to lower
HBC levels and might be prone to a higher susceptibility
to osteopenia.
In CF, the risk of osteopenia is a well known problem.
Therefore, in clinical practice, risk factors like nutrition
status, physical inactivity and use of corticosteroids are
closely monitored, and supplementation of vitamin D
and calcium is recommended w20x. Increasing knowledge
about vitamin K has led to its identification as another
risk factor for osteopenia. Recent recommendations only
propose vitamin K supplementation for patients with
liver disease, severe malabsorption, small bowel resec-
tion and for those under long-term antibiotic treatment
(European CF Nutrition Consensus Paper 2001, personal
communication). Yet, our study did not show an influ-
ence of the use of antibiotics on either HBC or PIVKA-
II. To monitor for vitamin K deficiency, customary blood
checks like coagulation assays are insufficient. Instead,
costly laboratory efforts would be necessary. However,
no matter whether choice of laboratory investigation
method yields a high w2x or a very low (this study)
proportion of vitamin K deficient patients, it appears
inappropriate to apply these expenditures on a routine
basis. For practical reasons, we would suggest that
routine vitamin K supplementation for all CF patients
with pancreatic insufficiency might be more appropriate
in order to avoid vitamin K deficiency of any tissue, as
recommended by Koletzko w21x. Whereas Beker et al.
w3x could not achieve normalisation of vitamin K levels,
PIVKA-II or HBC by supplementing 5 mg of vitamin
K weekly, our patients receiving supplementation1
between 6 and 20 mg vitamin K per week had even1
supranormal vitamin K plasma concentrations and no
markers of vitamin K deficiency detectable. While
recommended dosage of vitamin K is yet a matter of
discussion w2,22x, assessment of our data nevertheless
justifies the plea for general routine vitamin K supple-
mentation in cystic fibrosis patients.
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